Sandoz Pharma A.G.

16 articles with Sandoz Pharma A.G.

• Alteogen Enters Into an Exclusive License Agreement to Develop and Commercialize Biosimilar Products Enabled by Alteogen’s Hybrozyme™ Technology

  1/2/2023

  Alteogen Inc. announced that the company has entered into an exclusive license agreement with Sandoz AG.

• Polpharma Biologics Announces Global Commercialization Deal for Biosimilar Natalizumab, a Key Multiple Sclerosis Medicine

  9/3/2019

  Polpharma Biologics S.A. announces that it has entered a global commercialization agreement with Sandoz AG for a natalizumab biosimilar.

• Kit Check and Sandoz Agree to a Commercialization Collaboration That Helps Improve Hospital Medication Administration Safety

  6/27/2019

  Implementation of Kit Check RFID technology enables accuracy and visibility of hospital medications, from the production line to the patient

• Tilray® Signs Global Collaboration Agreement with Leading Pharmaceutical Company

  12/18/2018

  Tilray Canada Ltd., announced that it entered into a global framework agreement to collaborate with Sandoz AG, to increase availability of high quality medical cannabis products across the world.

• 7,000 Retailers Strike Against Novartis Corporation, Sandoz Pharma A.G.

  4/13/2009

• Novartis AG (JOBS) Unit Gets EU Approval for Generic Biosimilar

  2/13/2009

• Vectura Group plc Confirms Sandoz Pharma A.G. as Partner on VR315 and VR632

  9/9/2008

• Sandoz Pharma A.G. Launches Generic Version Of Toprol XL(R) 50 Mg ER Tablet

  8/3/2007

• Sandoz Pharma A.G. Receives FDA Approval for Generic Toprol XL(R) 50 mg Tablet

  5/21/2007

• FDA Warns Drugmakers Over Unapproved Headache Drugs, Companies Include: Novartis Pharma AG, Sandoz GmbH, IVAX Pharmaceuticals, Inc., and Teva Pharmaceutical Industries Limited

  3/2/2007

• Savient Pharmaceuticals, Inc. Files Patent Infringement Lawsuit Against Sandoz Pharmaceuticals And Upsher-Smith Laboratories

  12/4/2006

• The Day In Review: Momenta Pharmaceuticals, Inc. In Generic Deal With Novartis Corporation

  7/25/2006

• Teva Pharmaceutical Industries Limited Announces Novartis Corporation's Sandoz Pharma A.G. Unit Seeks To Delay First FDA Approval Of Generic Zocor(R)

  6/23/2006

• Sandoz Pharma A.G. Gets Precedent-Setting US Approval For Omnitrope(R) As First Follow-On Version Of A Previously Approved Recombinant Biotechnology Drug

  5/31/2006

• 340B Prime Vendor Program Adds Sandoz Pharmaceuticals To Growing List Of Companies Providing Low-Income Americans With Access To Antibiotic Injectibles And Oral Solid Medications

  4/11/2006

• FDA Rebuffs Novartis Pharma AG Over Delay To Biogeneric Drug

  11/15/2005